Stimatix GI's AOS-C1000, a colostomy management device designed to allow individuals to discretely manage their colostomy, has met primary and secondary endpoints in pre-clinical in-vivo animal studies.

As per the study, the primary endpoints of repeatable stoma sealing for continence control as well as secondary endpoints regarding tissue pathology and survival were met confirming the AOS-C1000 as capable of enabling repeatable colostomy site (stoma) sealing for continence control.

The AOS-C1000 is intended to improve quality of life and offer an elegant, non-surgical, and simple to use solution for round-the-clock continence control device, Stimatix GI said.

The AOS-C1000 colostomy management system seals the colostomy site without the use of adhesives, prevents leakage and odor.

Stimatix GI CEO David Hanuka said the pre-clinical results mark a breakthrough in ostomy care and people with colostomies face numerous obstacles including integrating back into society, difficulties with bag management, and skin irritation.